Tan Bjk, Davies Hd
Department of Pediatrics, University of Saskatchewan, Saskatoon, Saskatchewan;
Paediatr Child Health. 2002 Jul;7(6):390-7.
With the changing epidemiology of the etiological agents causing bacterial meningitis in Canada, the purposes of this study were to determine what empirical antibiotic(s) is/are advocated, and whether dexamethasone is recommended as adjunctive therapy by paediatric infectious diseases specialists for suspected meningitis caused by Streptococcus pneumoniae, Neisseria meningitides, Haemophilus influenzae type b, and partially treated (PT) bacterial meningitis.
A questionnaire invoking the specialists' preferred choices in treating bacterial meningitis was circulated by e-mail in March 1999 to 41 paediatric infectious diseases specialists or microbiologists (Paediatric Investigators Collaborative Network on Infections in Canada [PICNIC] members) who practised in 13 paediatric centres located in eight provinces.
Thirty-two (78% response rate) replies were received by July 1999 from 11 paediatric centres in seven provinces. Dexamethasone was recommended by 11 of 32 (34%) respondents for suspected S pneumoniae, four of 32 (12%) for suspected N meningitides, 18 of 32 (56%) for suspected H influenzae type b and five of 32 (16%) for suspected PT meningitis. A trend for more frequent recommended use of dexamethasone for S pneumoniae, H influenzae type b and N meningitides meningitis was found in eastern provinces (Ontario, Quebec and Nova Scotia), as opposed to the western provinces (Manitoba, Saskatchewan, Alberta and British Columbia). The most commonly recommended first line empirical antibiotic therapy was vancomycin plus 3rd-generation cephalosporin (V+3C). This was recommended by 27 of 32 (84%) respondents for suspected S pneumoniae, seven of 32 (22%) for suspected N meningitides, six of 32 (19%) for suspected H influenzae type b and 24 of 32 (75%) for PT meningitis; the remainder recommended using a 3C empirically for each type of meningitis. The major reason cited by respondents for using V+3C for suspected S pneumoniae was the presence of high-and intermediate-level penicillin-resistant S pneumoniae in their centres. No differences were found in the choice of antibiotic(s) between practitioners in the eastern and western provinces.
Although regional differences exist, the majority of paediatric infectious diseases experts no longer favour the use of dexamethasone for empirical therapy in most cases of bacterial meningitis. V+3C has become the regimen of choice in Canada for most cases of suspected bacterial meningitis.
随着加拿大细菌性脑膜炎致病病原体流行病学情况的变化,本研究旨在确定提倡使用哪种经验性抗生素,以及儿科传染病专家是否推荐将地塞米松作为由肺炎链球菌、脑膜炎奈瑟菌、b型流感嗜血杆菌引起的疑似脑膜炎以及部分治疗的(PT)细菌性脑膜炎的辅助治疗药物。
1999年3月通过电子邮件向在八个省份的13个儿科中心执业的41名儿科传染病专家或微生物学家(加拿大儿科感染协作网络[PICNIC]成员)发放了一份调查问卷,询问他们在治疗细菌性脑膜炎方面的首选方案。
到1999年7月,从七个省份的11个儿科中心收到了32份回复(回复率为78%)。在32名受访者中,11人(34%)推荐将地塞米松用于疑似肺炎链球菌感染,4人(12%)推荐用于疑似脑膜炎奈瑟菌感染,18人(56%)推荐用于疑似b型流感嗜血杆菌感染,5人(16%)推荐用于疑似部分治疗的脑膜炎。与西部省份(马尼托巴省、萨斯喀彻温省、艾伯塔省和不列颠哥伦比亚省)相比,在东部省份(安大略省、魁北克省和新斯科舍省),地塞米松用于肺炎链球菌、b型流感嗜血杆菌和脑膜炎奈瑟菌脑膜炎的推荐使用频率有增加的趋势。最常被推荐的一线经验性抗生素治疗方案是万古霉素加第三代头孢菌素(V+3C)。在32名受访者中,27人(84%)推荐将其用于疑似肺炎链球菌感染,7人(22%)推荐用于疑似脑膜炎奈瑟菌感染,6人(19%)推荐用于疑似b型流感嗜血杆菌感染,24人(75%)推荐用于部分治疗的脑膜炎;其余受访者推荐对每种类型的脑膜炎经验性使用一种第三代头孢菌素。受访者提及在疑似肺炎链球菌感染时使用V+3C的主要原因是其所在中心存在高水平和中度青霉素耐药的肺炎链球菌。东部和西部省份的从业者在抗生素选择上没有差异。
尽管存在地区差异,但大多数儿科传染病专家在大多数细菌性脑膜炎病例中不再倾向于将地塞米松用于经验性治疗。在加拿大,V+3C已成为大多数疑似细菌性脑膜炎病例的首选治疗方案。